Edgen Stock·Sep 21 2025, 05:30戻る
戻る
Johnson & Johnson's TREMFYA® Expands Ulcerative Colitis Treatment with Subcutaneous Option
Edgen Stock·Sep 21 2025, 05:30
[1] TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen[2] TREMFYA's Expansion into Ulcerative Colitis and Its Implications for Biotech Innovation[3] J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why | Nasdaq